TELA Bio (TELA) Liabilities and Shareholders Equity (2018 - 2026)

TELA Bio's Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $69.9 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 9.53% year-over-year to $69.9 million in Q1 2026; TTM through Mar 2026 was $280.4 million, a 1.22% increase from a year earlier, with the FY2025 full-year figure at $81.4 million, down 5.95% from the prior year.
• Liabilities and Shareholders Equity fell to $69.9 million in Q1 2026 per TELA's latest filing, from $81.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $94.4 million in Q2 2023 and bottomed at $51.3 million in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $69.9 million (2026), against an average of $70.7 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 83.87% in 2023 and slumped 39.28% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $67.9 million in 2022, then increased by 15.02% to $78.0 million in 2023, then gained by 10.92% to $86.6 million in 2024, then decreased by 5.95% to $81.4 million in 2025, then decreased by 14.16% to $69.9 million in 2026.
• Per Business Quant, the three latest TELA Liabilities and Shareholders Equity figures stand at $69.9 million (Q1 2026), $81.4 million (Q4 2025), and $61.6 million (Q3 2025).